News

Public · Published

CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position

CorMedix reported approximately $355 million in unaudited cash and cash equivalents as of September 30, 2026, and reaffirmed its 2026 total revenue guidance of $325 million to $345 million. It also said the CMS-set DefenCath add-on payment for the first quarter of 2027 will be $8.32 per dialysis session.

Published:

Updated:

What happened

CorMedix reported approximately $355 million in unaudited cash and cash equivalents as of September 30, 2026, and reaffirmed its 2026 total revenue guidance of $325 million to $345 million. It also said the CMS-set DefenCath add-on payment for the first quarter of 2027 will be $8.32 per dialysis session.

Confirmed

Global impact / market context

The $8.32 payment per dialysis session is a set add-on to the payment system for dialysis services. It may support revenue from DefenCath, but actual sales depend on how many sessions use the product; the article gives no utilization forecast or complete quarterly results.

Analyst inference

The company says the first-quarter 2027 add-on falls within its previously guided range of three to five times the current $2.37 payment. CMS also introduced a quarterly adjustment process, so later payment levels may change; CorMedix says it has not provided data to estimate them.

Analyst inference

What to watch

  1. CorMedix’s November 12 conference call is expected to provide its complete quarterly financial performance, adding detail beyond the cash position and annual revenue guidance reported here. Confirmed
  2. Watch for CMS’s quarterly adjustment process to clarify later 2027 add-on payments; those payment levels could affect revenue earned per DefenCath dialysis session. Analyst inference
  3. Compare future reported revenue with the reaffirmed $325 million to $345 million 2026 guidance, while checking whether the company gives new information on product use. Analyst inference

Evidence